Syndax Pharmaceuticals, Inc.SNDXNASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-274.90M
↓ 237% below average
Average (9y)
$-81.63M
Historical baseline
Range
High:$29.00M
Low:$-274.90M
CAGR
+68.8%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-274.90M | -71.2% |
| 2023 | $-160.60M | -19.9% |
| 2022 | $-133.90M | -561.7% |
| 2021 | $29.00M | +140.7% |
| 2020 | $-71.26M | -40.8% |
| 2019 | $-50.61M | +26.3% |
| 2018 | $-68.72M | -44.8% |
| 2017 | $-47.45M | -34.0% |
| 2016 | $-35.42M | -1329.9% |
| 2015 | $-2.48M | - |